GlassScriptPhysician profile
James Fairbairn
NPI 1356396923
$2,556.27
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $389 · 2021: $724 · 2022: $517 · 2023: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $402.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $620.38 | 2019-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $498.73 | 2019-2022 | |
| Pfizer INC. | $243.04 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $217.70 | 2021-2023 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.79 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $157.61 | 2019-2021 | |
| Abbvie INC. | $118.04 | 2021 | |
| Novo Nordisk INC | $107.94 | 2019-2022 | |
| Boston Scientific Corporation | $107.59 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $102.93 | 2019-2022 | |
| Preventric Diagnostics, INC. | $45.00 | 2021 | |
| Idorsia Pharmaceuticals US INC | $39.78 | 2022 | |
| Merck Sharp & Dohme LLC | $25.03 | 2019 | |
| Xeris Pharmaceuticals, INC. | $24.73 | 2022 | |
| Abbott Laboratories | $19.26 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16.84 | 2023 | Shingrix, Arexvy |
| Allergan, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fairbairn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.